About
Research & Development
Neurodegenerative Diseases
News & Publications
Contact

Who we are

About
PharmatrophiX

About Our mission, story, and approach.
Leadership Team, board, and scientific advisors
Peer Reviewed Funding & Investors

Our science

Research &
Development

Research & Development Our science and development philosophy.
Pipeline Programs and indications across our development stages.

Monthly Archives: February 2026

A better Alzheimer’s drug?

Posted on Feb 25, 2026

Stanford Medicine profiles LM11A-31 as a synapse-protective approach to slowing neurodegeneration.... Read More

Search

Recent Posts

Targeting Upstream Neurodegeneration: LM11A-31 in Alzheimer Disease and PSP
A better Alzheimer’s drug?
p75 receptor modulation slows biomarkers and preserves visuospatial function
New drug candidate targeting synaptic resilience well tolerated in Alzheimer’s patients
p75 neurotrophin receptor modulation in mild to moderate Alzheimer’s disease

Recent Comments

No comments to show.

Archives

May 2026
February 2026
December 2025
April 2025
May 2024
October 2023
February 2016
September 2015

Categories

Publication
Clinical
Corporate

A clinical-stage biopharmaceutical company developing therapies for neurodegenerative disease.

Company

About
Contact

Science

Research
Diseases

Resources

News & Publications

Follow

© 2026 PharmatrophiX, Inc. All rights reserved.

Terms
Privacy

TOP